NCT05301881

COntinue the SaMe Systemic Therapy After Local Ablative Therapy for Oligo Progression in Metastatic Breast Cancer - the COSMO Study

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 118 (estimated)
• Sponsor: The Netherlands Cancer Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Patients with oligoprogression of metastatic breast cancer during palliative treatment that is amenable to local therapy will be included. The local ablative therapy (LAT) may consist of stereotactic ablative radiotherapy (SABR), also known as stereotactic body radiation therapy, surgery or radiofrequency ablation (RFA).

Conditions

• Breast Cancer Invasive
• Metastatic Cancer
• Oligoprogressive

Interventions

Type	Name	Description
PROCEDURE	Surgery	resection of the oligometastatic lesion(s)
RADIATION	Radiotherapy	radiation of the oligometastatic lesion(s)
OTHER	Radiofrequent ablation	radiofrequent ablation of the oligometastatic lesion(s)

Timeline

• Start date: 2023-04-17
• Primary completion: 2035-04-01
• Completion: 2040-04-01
• First posted: 2022-03-31
• Last updated: 2025-02-05

Locations

7 sites across 1 country: Netherlands